Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. develops clinical-stage biotechnology programs for cancer and rare diseases. Company news centers on TARA-002, an investigational cell-based therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, including updates from the ADVANCED-2 trial in BCG-Unresponsive and BCG-Naïve NMIBC patient groups.
Recurring updates also cover IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving long-term parenteral support. Other company announcements include clinical-conference presentations, FDA designation updates, financial results, equity compensation grants under Nasdaq rules, and capital-raising activity tied to Protara's development-stage pipeline.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced participation in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 11:20 am ET in New York. The event aims to discuss the company’s efforts in developing transformative therapies for cancer and rare diseases. Protara’s lead program, TARA-002, is an investigational therapy for non-muscle invasive bladder cancer and lymphatic malformations. The webcast will be available on the Company’s website and archived for a limited period.
Protara Therapeutics (Nasdaq: TARA) has appointed Patrick Fabbio as Chief Financial Officer effective January 30, 2023. Fabbio brings over 30 years of experience from roles at Rafael Holdings and other pharmaceutical companies. CEO Jesse Shefferman expressed confidence in Fabbio's financial expertise to advance Protara's lead candidate, TARA-002, aimed at treating non-muscle invasive bladder cancer and lymphatic malformations. Fabbio received an inducement grant of options to purchase 300,000 shares at the closing price on his start date, set to vest over four years, enhancing stakeholder interest in the company's future prospects.
Protara Therapeutics (Nasdaq: TARA) announced the presentation of a Trials in Progress poster at the Annual Meeting of the Society of Urologic Oncology from November 30 to December 2, 2022. The poster highlights the ADVANCED-1 Phase 1 trial for the investigational therapy TARA-002, targeting non-muscle invasive bladder cancer (NMIBC). With a focus on an underserved patient population, the study aims to evaluate TARA-002's safety and preliminary anti-tumor activity. The trial is crucial for establishing a recommended dose for future clinical phases.
Protara Therapeutics (TARA) reported third quarter 2022 results, highlighting ongoing dose escalation in the Phase 1 ADVANCED-1 study for TARA-002 targeting non-muscle invasive bladder cancer. The company received FDA feedback for a proposed Phase 2 study in lymphatic malformations, expected to start in 2023. Financially, Protara holds $107.1 million in cash, projected to fund operations into 2H2024. R&D expenses dropped to $3.5 million, while net loss decreased to $7.7 million, or $0.68 per share, compared to $10.8 million, or $0.96 per share, in 2021.
Protara Therapeutics (Nasdaq: TARA) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. A prerecorded presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET. Interested parties can access the presentation via the Events and Presentations section of Protara's website. Protara is focused on developing transformative therapies for cancer and rare diseases, including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.
Protara Therapeutics (Nasdaq: TARA) reported significant progress in its Phase 1 ADVANCED-1 study of TARA-002 for non-muscle invasive bladder cancer. As of June 30, 2022, the company holds a robust cash position of $112.8 million, sufficient to fund operations into mid-2024. R&D expenses decreased to $3.1 million, while general and administrative expenses fell to $5.6 million, leading to a reduced net loss of $8.5 million or $0.80 per share. Protara is also advancing TARA-002's development for lymphatic malformations and continues its study on IV Choline Chloride for intestinal failure.
Protara Therapeutics (TARA) announced that its Chief Financial Officer, Blaine Davis, will leave the company on July 15, 2022, to pursue other opportunities. His departure is not linked to the company's operations or financial reporting. As of March 31, 2022, Protara had cash and investments of $119 million, expected to fund operations into mid-2024. CEO Jesse Shefferman acknowledged Davis's contributions, highlighting the strength of the finance and operational teams. Protara focuses on developing transformative therapies, including TARA-002 for bladder cancer and lymphatic malformations.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced plans to present a Trials in Progress poster on TARA-002 at the American Society of Clinical Oncology Annual Meeting from June 3-7, 2022. The ADVANCED-1 Phase 1 trial aims to evaluate TARA-002, an investigational immunopotentiator for non-muscle invasive bladder cancer (NMIBC). The trial is designed to assess the safety and preliminary anti-tumor activity of TARA-002 in treatment-naïve and experienced patients. Approximately 65,000 NMIBC cases are diagnosed annually in the U.S., emphasizing the need for new treatment options.
Protara Therapeutics, Inc. (Nasdaq: TARA) has announced its participation in the H.C. Wainwright Global Investment Conference from May 23 to May 26, 2022. Their prerecorded presentation will be available on May 24, 2022, at 7:00 a.m. ET. Interested viewers can access it via the Events and Presentations section of Protara's website, where it will be archived for 90 days. Protara focuses on developing therapies for cancer and rare diseases, including TARA-002 for bladder cancer and IV Choline Chloride for intestinal failure-related liver disease.
Protara Therapeutics (Nasdaq: TARA) announced positive results from a retrospective analysis of OK-432, the basis for its investigational therapy TARA-002, targeting lymphatic malformations (LMs). Presented at the ISSVA World Congress 2022, the analysis involved 246 patients, showing approximately 69% clinical success in immediate treatment groups versus 7.5% in delayed groups. Serious adverse events were rare, with a favorable safety profile noted. These findings bolster the potential for TARA-002 to provide a much-needed FDA-approved treatment for LMs.